alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 776–800 of 842 studies (page 32 of 34) · 27,380 in the whole library · How the 0–100 score works

Showing 842 studies tagged classification — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Progression-Aware and Explainable CNN–Transformer Framework for Multiclass Alzheimer’s Disease Staging Using MRI

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Diagnostics 2026-02-16

The experimental findings on a multiclass MRI dataset of Alzheimer disease demonstrate consistent and high performance across cross-validation folds (mean F1-score (0.991 ± 0.003) and AUROC (0.9998 ± 0.0002)), without losing transparency and progress awareness. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

‘Machine Learning’ multiclassification for stage diagnosis of Alzheimer’s disease utilizing augmented blood gene expression and feature fusion

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Discover Applied Sciences 2025-06-12

Three blood gene expression datasets of high dimensionality and low sample size (HDLSS) have been utilized in this study, with one dataset exhibiting significant class imbalance. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Graph Spectral Analysis Using Electroencephalography in Alzheimer Disease and Frontotemporal Dementia Patients

✓ Peer-reviewed alzhub usefulness score 35 out of 100. International Journal of Neural Systems 2025-06-12

Graph theory has proven to be useful in studying brain dysfunction in Alzheimer’s disease using MagnetoEncephaloGraphy (MEG) and fMRI signals. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Assessing Co‐Localization of ITM2B With Alzheimer's Disease and Limbic‐Predominant Age‐Related TDP ‐43 Encephalopathy Neuropathologic Changes

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Neuropathology 2025-03-05

Mutations in the Integral membrane protein 2B (ITM2B) gene are linked to the development of familial British and Danish dementias, two relatively early-onset dementia disorders known also to be associated with Tau neurofibrillary tangles (NFTs). 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Pharmaceuticals (Basel, Switzerland) 2025-01-08

Florbetaben (FBB) is a radiopharmaceutical approved by the FDA and EMA in 2014 for the positron emission tomography (PET) imaging of brain amyloid deposition in patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Attention Networks Connectivity After Cognitive Rehabilitation in Alzheimer’s Disease

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Journal of Geriatric Psychiatry and Neurology 2026-06-17

Enhanced connectivity between attention networks may be a characteristic of CR benefits in individuals with mild Alzheimer disease. 3 key findings →

Participants: 22 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Detecting Mild Cognitive Impairment to Alzheimer’s Disease Progression by fMRI Using Convolutional Neural Network and Long-short Term Memory

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Basic and Clinical Neuroscience Journal 2025-11-01

The results showed that the best validation scores were achieved by the CNN-LSTM model after integrating clinical attributes, with an accuracy of 92.47%. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2015-07-01

We determined that several iterations of the discriminant analysis improved the classification of subjects into the AβL and AβH groups. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Agentic artificial intelligence in cognitive screening: A translational roadmap for dementia care

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Journal of Alzheimer s Disease Reports 2025-01-01

Conventional dementia screening tools, whether paper tests or static artificial intelligence (AI) models, capture only a snapshot of cognition and need to be adminstered periodically. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Machine learning–enhanced screening funnel for clinical trials in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer s & Dementia Translational Research & Clinical Interventions 2025-04-01

This approach predicts clinical progression (2-year Clinical Dementia Rating Sum of Boxes change > 1) with an area under the curve of 0.836. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multi-omics profiling reveals two distinct trajectories in the progression from mild cognitive impairment to Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Journal of Alzheimer s Disease 2025-08-06

BackgroundAlzheimer's disease (AD) exhibits significant clinical and pathological heterogeneity, particularly during the mild cognitive impairment (MCI) transitional stage. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Quantitative EEG obtained from Dual‐Task paradigms for the study of preclinical populations at risk of Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer s & Dementia 2025-12-01

The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha-1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task. 5 key findings →

Participants: 37 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Quantitative EEG obtained from Dual‐Task paradigms for the study of preclinical populations at risk of Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer s & Dementia 2025-12-01

The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha-1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task. 5 key findings →

Participants: 37 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From across this tag

10 of the 838 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed